Feasibility, safety and efficacy of concomitant curcumin in patients undergoing palliative radiotherapy for FIGO stage IIIB–IVA cervical cancer: An open-label pilot trial

Abstract

The rationale for combining curcumin with radiotherapy in the context of treating stage IIIB-IVA cervical cancer aims to enhance therapeutic efficacy while mitigating treatment related toxicities. Envisaged synergies between curcumin and radiotherapy, coupled with the potential reduction in radiation-induced toxicities, offer a promising pathway to advance treatment strategies and enhance patient care standards in these challenging clinical situations. To enhance the bioavailability, novel curcumin formulation, CurQfenTM or curcumagalactomannoside (CGM), is used.